DEFC14A: AREX Capital Seeks Board Overhaul at Enhabit, Citing Underperformance

AREX Capital, a significant Enhabit stockholder, is soliciting proxies to elect its seven nominees to the board, aiming to address what it perceives as the company's underperformance and strategic missteps.

Summary

• AREX Capital Master Fund, LP, along with its affiliates, is seeking to elect seven nominees to Enhabit's Board of Directors at the upcoming annual meeting on July 25, 2024.
• AREX owns approximately 4.9% of Enhabit's outstanding common stock.
• AREX believes that the current board has failed to adequately supervise the company's management team, leading to a significant decline in the company's share price.
• AREX is also soliciting proxies for two of the company's nominees, Barbara A. Jacobsmeyer and Barry P. Schochet, whose election they do not oppose.
• The annual meeting will be held virtually on July 25, 2024, at 9:00 a.m. (CDT).
• AREX urges stockholders to vote using the WHITE universal proxy card to elect all seven AREX nominees and the two unopposed company nominees.
• The record date for determining stockholders eligible to vote at the Annual Meeting was June 5, 2024.
• As of the record date, there were 50,156,310 shares of common stock outstanding and entitled to vote at the Annual Meeting.

Sentiment

Score: 3

Explanation: The document expresses strong dissatisfaction with the current board and management, highlighting significant underperformance and strategic missteps. The tone is critical and aims to instigate change.

Positives

• AREX believes Enhabit is well-positioned to compete in the home health and hospice industries.
• AREX applauds Enhabit's decision to launch a strategic alternatives process.
• AREX believes the AREX Nominees will bring necessary experience and improved oversight to the boardroom.

Negatives

• AREX believes Enhabit's stockholders have suffered from the Board's failure to adequately supervise the Company's inexperienced management team.
• AREX criticizes the Board for rejecting director candidates with highly relevant experience.
• AREX believes the current Board has utterly failed in its stewardship of the Company.

Risks

• If fewer than five of the AREX Nominees are elected, they will comprise less than a majority of the Board and there can be no guarantee that the AREX Nominees will be able to implement the actions that they believe are necessary to unlock stockholder value.
• There is no assurance that any of the Company's nominees will serve as directors if all or some of the AREX Nominees are elected.
• If AREX is successful in obtaining stockholder approval for the election of five (5) or more of the AREX Nominees at the Annual Meeting, then a change of control of the Board may be deemed to have occurred under certain of the Company's material agreements and contracts.

Future Outlook

AREX intends to vote the AREX Shares FOR the AREX Nominees and the Unopposed Company Nominees, FOR the ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm, and FOR the approval of the advisory vote on the compensation of the Company's named executive officers, as described herein.

Management Comments

• AREX believes Enhabit is well-positioned to compete in the highly fragmented and secularly growing home health and hospice industries.
• AREX believes Enhabit's stockholders have suffered from the Board's failure to adequately supervise the Company's inexperienced management team.
• AREX believes the AREX Nominees will bring necessary experience and improved oversight to the boardroom.

Industry Context

The document references the acquisition of Amedisys, Inc. by Option Care Health, Inc. as evidence of strategic interest in home health assets.

Comparison to Industry Standards

• The document compares Enhabit's total stockholder return to its 2024 Compensation Peer Group, which includes companies like Addus HomeCare Corporation, Amedisys, Inc., and Aveanna Healthcare Holdings, Inc.
• Enhabit's underperformance versus its proxy peer set is cited as 50.8% over a two-year period and 25.3% over a one-year period.

Stakeholder Impact

• The outcome of the proxy vote will significantly impact Enhabit's board composition and strategic direction, affecting shareholders, employees, and other stakeholders.
• AREX believes that a reconstituted board will enhance value for all Enhabit stockholders.

Next Steps

• Stockholders are urged to vote using the WHITE universal proxy card to elect the AREX nominees and the unopposed company nominees.
• The Annual Meeting will be held virtually on July 25, 2024, where stockholders can vote and submit questions.

Key Dates

Keywords

proxy solicitation, board of directors, AREX Capital, Enhabit, nominees, stockholders, annual meeting, corporate governance